Commons RJ

Grivas R

Currie, Bart

2014-12-01

Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.

Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia..

Intern Med J . 2014 Dec;44(12a):1245-6. doi: 10.1111/imj.12610.

https://pubmed.ncbi.nlm.nih.gov/25442759/?otool=iaurydwlib

https://hdl.handle.net/10137/5535

Burkholderia pseudomallei

immunosuppression

melioidosis

monoclonal antibody

psoriatic arthritis

Adalimumab

Amoxicillin-Potassium Clavulanate Combination

Anti-Infective Agents

Antibodies, Monoclonal, Humanized

Antirheumatic Agents

Arthritis, Psoriatic

Burkholderia pseudomallei

Humans

Male

Melioidosis

Middle Aged

Risk Factors

Treatment Outcome

Trimethoprim, Sulfamethoxazole Drug Combination

Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis.

Journal Article

Publication